{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.1","upperLimit":"27.4","value":"19.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"description":"Time to progression (TTP) was calculated as the time from randomization to the first documented progression confirmed by the investigator and based on the International Myeloma Working Group Uniform Response criteria (IMWG).\n\nProgressive disease requires 1 of the following:\n\n* Increase of ≥ 25% from nadir in:\n\n  * Serum M-component (absolute increase ≥ 0.5 g/dl)\n  * Urine M-component (absolute increase ≥ 200 mg/24 hours)\n  * In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase \\> 100 mg/dl)\n  * Bone marrow plasma cell percentage (absolute % ≥ 10%)\n* Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas.\n* Development of hypercalcemia (corrected serum calcium \\> 11.5 mg/dl) attributed solely to plasma cell proliferative disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Oral pomalidomide 4 mg on Days 1-21 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity","id":"OG000","title":"Pomalidomide"}],"paramType":"MEDIAN","populationDescription":"Intent to Treat includes all participants enrolled","reportingStatus":"POSTED","timeFrame":"From randomization through the follow-up phase; up to the data-cut off of 31 July 2014; Maximum time to progression follow-up was 90.3 weeks.","title":"Kaplan-Meier Estimate for Time to Progression (TTP) Based on Investigator Assessment Using IMWG Criteria","type":"SECONDARY","unitOfMeasure":"weeks"}